1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Klaria Pharma Holding AB (publ.)

Klaria Pharma Holding AB (publ.)

KLAR.ST
Klaria Pharma Holding AB (publ.)SE flagStockholm Stock Exchange
0.77
SEK
-0.02
- -
261.63MMarket Cap
Klaria Pharma Holding AB (publ.)
KLAR.ST
(Stockholm Stock Exchange)

Recent

price

0.77

P/E

ratio

- -

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
0.07
- -
0.12
- -
- -
0.1
0.08
0.02
0.05
- -
Revenue per Share
- -
-0.3
-0.44
-0.65
-0.81
-0.66
-1.09
-0.94
-1.07
-0.35
-0.38
-0.21
-0.21
Basic EPS, GAAP
- -
-0.23
-0.44
-0.36
-0.27
-0.43
-0.75
-0.44
-0.84
-0.09
-0.1
-0.19
-0.17
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
-0.27
-0.43
-1.89
-2.69
-3.31
-2.72
-2.98
-1.63
-2.3
-2.36
-0.18
-0.02
Book Value per Share
- -
2.35
0.91
0.47
-0.06
-0.43
0.22
-0.34
-0.04
-0.26
-0.4
-0.22
-0.22
Tangible Book Value per Share
- -
19
33
33
34
34
47
57
60
103
125
189
214
Basic Weighted Avg Shares
- -
- -
- -
2
- -
4
- -
- -
6
8
2
9
- -
Sales/Revenue/Turnover
- -
- -
- -
-959.82
- -
-499.83
- -
- -
-944.79
-380.7
-1,388.21
-280.72
-24,767.13
Operating Margin (%)
- -
- -
- -
10
10
10
13
11
11
11
11
11
11
Depreciation Expense
- -
-6
-15
-22
-27
-22
-51
-54
-64
-36
-48
-39
-46
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
-948.04
- -
-532.61
- -
- -
-1,086.81
-423.28
-2,124.11
-432.8
-32,132.87
Profit Margin (%)
- -
45
30
16
-2
-15
10
-20
-3
-27
-50
-42
-38
Working Capital
- -
- -
- -
- -
- -
- -
- -
1
- -
- -
1
- -
- -
LT Debt
- -
175
160
122
95
82
110
69
76
41
3
-4
-21
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
246
246
246
Market Capitalization
82
126
180

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
5
2
2
Cash, Cash Equivalents & STI
3
- -
- -
Accounts Receivable, Net
3
2
2
Inventories
- -
- -
- -
Total Current Liabilities
42
44
41
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-41.65%
-76.44%
-217.25%
Free Cash Flow
60.08%
42.89%
193.57%
Net Income, GAAP
34.02%
-1.16%
-18.56%
Sales/Revenue/Turnover
- -
- -
299.69%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
1
1
2
2025
9
- -
- -
- -
9
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.11
-0.11
-0.06
-0.11
-0.38
2025
-0.01
-0.14
-0.04
-0.03
-0.21
2026
-0.04
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
The Flowr Corporation (FLWPF)
Acusphere, Inc. (ACUS)
Avant Brands Inc. (AVNT.TO)
Toho Holdings Co., Ltd. (8129.T)
Prince Pharmaceutical Co., Ltd. (6935.TWO)
Transnational Cannabis Ltd. (TRCNF)
Business
Klaria Pharma Holding AB (publ.) operates as a pharmaceutical firm, headquartered in Uppsala, Sweden, since its establishment in 2014. The company develops innovative, fast-acting drug formulations utilizing its proprietary and patented alginate film technology, designed for efficient delivery via the oral mucosa. This method allows active substances to be absorbed directly into the bloodstream, circumventing traditional oral administration and providing a beneficial alternative to injections or nasal sprays. Its portfolio includes treatments like Sumatriptan Alginate Film, which secured market approval in major European countries in August 2024 for migraine management and is slated for initial commercial release in the latter half of 2025. The pipeline also features several clinical-stage assets, such as Epinephrine Alginate Film for severe allergic reactions, Naloxone Alginate Film to address opioid overdose, Midazolam Alginate Film for acute epilepsy, and Ketamine Alginate Film for acute pain and depression. Additionally, through its subsidiary Cannabis Delivery Sciences, Klaria explores the commercial potential of its film technology for various cannabinoid applications, encompassing both medicinal and recreational uses of compounds like THC and CBD.